Phase I Study of RiMO-401 With Radiation in Advanced Tumors

Summary

This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.

Timeline

Start

2024-02-22

Primary completion

2025-06-16

Completion

2025-06-16

Outcome

Outcome not reported

Stopped (Enrollment): “slow enrollment”

Drugs

Indications